MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Bayer AG

Closed

SectorFinance

26.36 -0.17

Overview

Share price change

24h

Current

Min

26.185

Max

26.905

Key metrics

By Trading Economics

Income

1.6B

1.3B

Sales

2B

14B

P/E

Sector Avg

30.9

24.968

EPS

2.49

Dividend yield

0.44

Profit margin

9.492

Employees

90,885

EBITDA

1.9B

3.6B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+4.98% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.44%

4.18%

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

3.5B

25B

Previous open

26.53

Previous close

26.36

News Sentiment

By Acuity

28%

72%

88 / 538 Finance

Technical Score

By Trading Central

Confidence

Bearish Evidence

Bayer AG Chart

Past performance is not a reliable indicator of future results.

Related News

13 May 2025, 08:22 UTC

Earnings
Major Market Movers

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13 May 2025, 06:09 UTC

Earnings

Bayer Confirms Guidance Despite Net Profit Drop

24 Mar 2025, 09:37 UTC

Major Market Movers

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 Jun 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 May 2025, 13:47 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27 May 2025, 12:22 UTC

Market Talk
Earnings

Bayer's Prospects Are Improving -- Market Talk

16 May 2025, 13:42 UTC

Hot Stocks

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 May 2025, 08:57 UTC

Hot Stocks

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15 May 2025, 22:46 UTC

Top News
Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13 May 2025, 06:50 UTC

Market Talk
Earnings

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13 May 2025, 05:36 UTC

Earnings

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13 May 2025, 05:35 UTC

Earnings

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13 May 2025, 05:34 UTC

Earnings

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13 May 2025, 05:34 UTC

Earnings

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13 May 2025, 05:32 UTC

Earnings

Bayer 1Q EPS EUR2.49

13 May 2025, 05:32 UTC

Earnings

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13 May 2025, 05:32 UTC

Earnings

Bayer 1Q Ebitda Before Special Items EUR4.085B

13 May 2025, 05:31 UTC

Earnings

Bayer 1Q EBIT EUR2.32B

13 May 2025, 05:31 UTC

Earnings

Bayer 1Q Net Pft EUR1.30B

13 May 2025, 05:31 UTC

Earnings

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13 May 2025, 05:30 UTC

Earnings

Analysts Saw Bayer 1Q Sales at EUR13.41B

13 May 2025, 05:30 UTC

Earnings

Bayer 1Q Sales EUR13.74B

13 May 2025, 05:30 UTC

Earnings

Bayer Backs 2025 View

14 Apr 2025, 13:00 UTC

Top News

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7 Apr 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2 Apr 2025, 09:27 UTC

Hot Stocks

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 Mar 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

4.98% upside

12 Months Forecast

Average 26.58 EUR  4.98%

High 33 EUR

Low 20 EUR

Based on 13 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

13 ratings

3

Buy

10

Hold

0

Sell

Technical Score

By Trading Central

22.99 / 23.88Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

88 / 538 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.